Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Alanyl-tRNA synthetase fragment binds to FGFR4 and induces morphological changes and downstream signaling in liver cells with functional similarities to FGF2

Tuesday, March 26, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the binding of an alanyl-tRNA synthetase fragment to FGFR4, which leads to morphological changes and downstream signaling in liver cells. This mechanism exhibits functional similarities to FGF2, suggesting potential therapeutic applications. The findings underscore the significance of extracellular tRNA synthetase biology in liver cell function.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alanyl-tRNA synthetase fragment shows potential in liver cell signaling.
  • Induces morphological changes similar to FGF2, indicating therapeutic promise.
  • Highlights innovative research in extracellular tRNA synthetase biology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What does the alanyl-tRNA synthetase fragment do?

It binds to FGFR4 and induces morphological changes in liver cells.

How does the fragment affect liver cells?

It triggers downstream signaling similar to the effects of FGF2.

What is the significance of this research?

It highlights potential therapeutic applications in liver cell function.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare FGFR4 liver cells alanyl-tRNA synthetase extracellular biology
Last updated: Mar 26, 2024

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →